0000000000175392

AUTHOR

L Ricci

showing 3 related works from this author

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

2018

Correction to: Internal and Emergency Medicine (2018) 13:651–660 https://doi.org/10.1007/s11739-018-1835-9 In the original publication, one of the ARAPACIS collaborators Dr. “Leonardo Di Gennaro” name has been erroneously mentioned as “Leonardo De Gennaro”.

medicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryInternal Medicine; Emergency MedicineEmergency medicineEmergency MedicineInternal MedicinemedicineNon valvular atrial fibrillationPulmonary diseasebusinessInternal and emergency medicine
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct